Related Experiment Video
Updated: Mar 3, 2026

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
Dexrazoxane for cardioprotection in older adults with acute myeloid leukemia
Pankit Vachhani1, Sarah Shin2, Jeffrey Baron3
1Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, USA.
Abstract:
Anthracyclines constitute the backbone of intensive adult acute myeloid leukemia (AML) therapy. Cardiotoxicity is one of its most serious adverse effects, and its incidence increases with cumulative dose. Dexrazoxane is a cardioprotective agent used in conjunction with anthracycline therapy. There is limited data of its usage in adult AML patients. We report the outcomes of six older adults at high risk of anthracycline-induced cardiotoxicity who received dexrazoxane during induction/re-induction therapy. Five had preserved left-ventricular function while two proceeded onto stem-cell transplantation. Additional investigation of dexrazoxane in adult leukemia therapy is warranted, particularly in older patients at highest risk for cardiovascular mortality.
Related Concept Videos
Drug Dosing: Geriatric Patients
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacodynamics in Geriatric Patients: Effects of Age
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Cardiomyopathy IV: Restrictive Cardiomyopathy

